Patients with gastrointestinal tumors may have increased risk of developing other cancers
the ONA take:
According to a recent study published in the journal Cancer, researchers at the University of California San Diego School of Medicine have found that patients with gastrointestinal stromal tumors (GIST) have a higher risk of developing additional malignancies before and after their diagnosis of GIST.
Specifically, the study showed that one in 5.8 patients with GIST will develop other sarcomas, carcinoid tumors, non-Hodgkin's lymphoma, melanoma, breast, colorectal, esophageal, hepatobiliary, non-small cell lung, pancreatic, prostate, and renal cell cancers.
Results also showed that when compared to the general U.S. population, patients with GIST had a 44% increased prevalence of cancers occurring before a diagnosis of GIST and a 66% increased risk of developed other cancers following diagnosis.
"Patients diagnosed with gastrointestinal stromal tumors may warrant consideration for additional screenings based on the other cancers that they are most susceptible to contract," said co-author James D. Murphy, MD, assistant professor of radiation oncology and UC San Diego Moores Cancer Center radiation oncologist.
Patients with gastrointestinal stromal tumors have a higher risk of developing additional malignancies before and after diagnosis.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|